Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BIIB vs ADVM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BIIB Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

BIIB Overall Winner 6-Pillar Tally: BIIB 6 – 0 ADVM Matrix Metrics: BIIB 8 – 2 ADVM

As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Adverum Biotechnologies, Inc. (ADVM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BIIB carries a Unified Composite Score of 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin), whereas ADVM carries 62.4/100 (BUY) at $4.36 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ADVM currently prints a higher short-term Unified Composite Score (62.4/100 BUY vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (23.5% vs. 0.0% operating margin) and revenue trajectory (+10.6% vs. -70.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BIIB vs ADVM
BIIB NASDAQ Head-to-Head Winner
Biogen Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$252.72
-0.27% 1D
Market Cap $37.0B
TTM Revenue $10.3B
Forward P/E 15.6x
Beta / 30D Vol 0.27β · 36% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 45.0 Fund 52.0 Flow 64.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.3% over 20 days), RSI 60
RSI-14: 60.3 · SMA20: $250.29 · SMA50: $234.03
ADVM NASDAQ
Adverum Biotechnologies, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.36
+4.06% 1D
Market Cap $91.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.04β · 17% Vol
Unified Composite Score
62.4 / 100 BUY
Tech 60.0 Fund 57.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.0 · SMA20: $4.21 · SMA50: $4.41

6-Pillar Scorecard Institutional Category Breakdown (BIIB 6 – 0 ADVM)

Columns: Metric · BIIB · ADVM
1. Valuation Multiples BIIB
Forward P/E 15.6x N/M
Trailing P/E 109.9x N/M
PEG Ratio 3.45x N/M
EV / Revenue 4.2x N/M
2. Growth & Scale BIIB
Revenue Growth (YoY) +10.6% -70.0%
Earnings Growth (YoY) -84.8% +0.0%
TTM Revenue (USD) $10.3B N/A
Market Cap $37.0B $91.8M
3. Profitability & Quality BIIB
Gross Margin 75.8% N/A
Operating Margin 23.5% 0.0%
Net Profit Margin 3.4% 0.0%
Return on Equity (ROE) 1.9% -417.8%
4. Balance Sheet & Cash Flow BIIB
Cash Generation (TTM) $1.64B N/A
Cash Flow Margin 16.0% N/A
Net Cash / Leverage $6.50B Net Debt (0.41x D/E) -417.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BIIB
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 18.4% (6th %ile) 30.2% (10th %ile)
Put/Call OI Skew 0.77x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat BIIB
OpEx & R&D Intensity 52.3% of Rev ($5.39B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - General Operator Biological Products, (No Disgnostic Substances) Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BIIB (8) vs ADVM (2)
Institutional Metric BIIB ADVM Criterion Row Edge
Market Capitalization
Scale
$37.0B $91.8M Larger Scale BIIB
Trailing P/E Ratio
Valuation
109.9x N/M Lower Multiple BIIB
Forward P/E Ratio
Valuation
15.6x N/M Lower Multiple BIIB
Revenue Growth (YoY)
Growth
+10.6% -70.0% Higher Growth BIIB
Operating Margin (TTM)
Profitability
23.5% 0.0% Higher Margin BIIB
Net Profit Margin
Profitability
3.4% 0.0% Higher Margin BIIB
Return on Equity (ROE)
Capital Efficiency
1.9% -417.8% Higher ROE BIIB
52-Week Range Position
Momentum
92% ($160–$261) 55% ($2–$6) Stronger Trend BIIB
Beta / 30D Volatility
Risk Regime
0.27β · 36% Vol 1.04β · 17% Vol Lower Realized Risk ADVM
Unified Institutional Score
Composite Signal
50.2 / 100 (HOLD) 62.4 / 100 (BUY) Higher Composite ADVM
Trailing 12M Revenue (USD)
Operating Scale
$10.3B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.45x PEG · 4.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.64B ($6.50B Net Debt (0.41x D/E)) N/A (-417.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BIIB +7.19 pp
BIIB: +9.54% · ADVM: +2.35%
3M Horizon BIIB +7.19 pp
BIIB: +9.54% · ADVM: +2.35%
6M Horizon BIIB +7.19 pp
BIIB: +9.54% · ADVM: +2.35%
1Y Horizon BIIB +7.19 pp
BIIB: +9.54% · ADVM: +2.35%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BIIB vs ADVM. Trailing 12-month operating profitability (BIIB 23.5% vs ADVM 0.0%) and valuation multiples (BIIB 15.6x vs ADVM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BIIB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$10.3B
Gross Margin75.8%
Op. Margin23.5%
ROE / Fwd P/E1.9% · 15.6x
ADVM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-417.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BIIB CONSOLIDATION
17d in phase · OBV ACCUMULATION
Current IV 18.4%
IV Percentile 6th %ile
Put/Call OI Skew 0.77x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact BIIB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ADVM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 30.2%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ADVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BIIB Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $37.0B market capitalization and 23.5% operating margin.
OpEx & R&D Reinvestment 52.3% of Rev ($5.39B)
90D Engineering Disclosures 0 Published
ADVM Moat Profile Cyclical / Execution-Driven Positioning
Biological Products, (No Disgnostic Substances) Operator
Competes within the Biological Products, (No Disgnostic Substances) value chain with $91.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BIIB vs ADVM Key Questions & Quantitative Answers

As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Adverum Biotechnologies, Inc. (ADVM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BIIB carries a Unified Composite Score of 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin), whereas ADVM carries 62.4/100 (BUY) at $4.36 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ADVM currently prints a higher short-term Unified Composite Score (62.4/100 BUY vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (23.5% vs. 0.0% operating margin) and revenue trajectory (+10.6% vs. -70.0% YoY).

BIIB leads the Growth & Scale pillar: BIIB posts +10.6% YoY revenue growth and -84.8% YoY earnings growth on $10.3B TTM revenue (75.8% gross margin, 23.5% operating margin), compared with ADVM at -70.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, BIIB generates $10.3B in USD-normalized revenue versus N/A for ADVM. In operating R&D and SG&A reinvestment, BIIB deploys 52.3% of Rev ($5.39B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ADVM.

BIIB screens cheaper on headline valuation multiples. BIIB trades at 15.6x Forward P/E, 109.9x Trailing P/E, 3.45x PEG, and 4.2x EV/Revenue (16.0% FCF margin), whereas ADVM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BIIB (1.9% ROE) versus ADVM (-417.8% ROE) capital efficiency.

In options market volatility and institutional positioning, BIIB carries 18.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 36% Vol realized risk). By comparison, ADVM carries 30.2% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 17% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.